TESTOSTERONE PROPIONATE Drug Patent Profile

When do Testosterone Propionate patents expire, and when can generic versions of Testosterone Propionate launch?

Testosterone Propionate is a drug marketed by Bel Mar, Elkins Sinn, Lilly, and Watson Labs. and is included in eight NDAs.

The generic ingredient in TESTOSTERONE PROPIONATE is testosterone propionate. There is one drug master file entry for this compound. Additional details are available on the testosterone propionate profile page.

Summary for TESTOSTERONE PROPIONATE

US Patents:	0
Applicants:	4
NDAs:	8
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	3
Patent Applications:	6,473
DailyMed Link:	TESTOSTERONE PROPIONATE at DailyMed

Recent Clinical Trials for TESTOSTERONE PROPIONATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Texas at Austin	Phase 4
University of Texas at Austin	N/A
University of Vermont	Phase 1/Phase 2

See all TESTOSTERONE PROPIONATE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for TESTOSTERONE PROPIONATE

G03BA	3-oxoandrosten (4) derivatives
G03B	ANDROGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for TESTOSTERONE PROPIONATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bel Mar	TESTOSTERONE PROPIONATE	testosterone propionate	INJECTABLE;INJECTION	080741-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Watson Labs	TESTOSTERONE PROPIONATE	testosterone propionate	INJECTABLE;INJECTION	085490-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Elkins Sinn	TESTOSTERONE PROPIONATE	testosterone propionate	INJECTABLE;INJECTION	080276-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Watson Labs	TESTOSTERONE PROPIONATE	testosterone propionate	INJECTABLE;INJECTION	080188-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Bel Mar	TESTOSTERONE PROPIONATE	testosterone propionate	INJECTABLE;INJECTION	080742-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Testosterone Propionate Market Dynamics, Patent Status, and Financial Trajectory

Last updated: September 7, 2026

Testosterone propionate is a mature, short-acting injectable androgen with limited commercial scale relative to testosterone cypionate, testosterone enanthate, testosterone undecanoate, topical gels, and implantable pellets. Its patent risk is low because the active ingredient and ester chemistry are long established. The main commercial constraints are short dosing intervals, limited mainstream prescribing, controlled-substance regulation, manufacturing economics, and competition from longer-acting testosterone products.

No major pharmaceutical company publicly reports testosterone propionate revenue as a separate product line. Its financial trajectory is therefore best assessed through product availability, generic competition, testosterone-replacement-therapy demand, regulatory conditions, and the economics of small-volume injectable products.

What is testosterone propionate and how is it used?

Testosterone propionate is an esterified form of testosterone administered by intramuscular injection. The ester delays testosterone release after injection but produces a shorter duration of action than testosterone cypionate or testosterone enanthate.

Attribute	Testosterone propionate
Active ingredient	Testosterone propionate
Drug class	Androgen; anabolic steroid
Administration	Intramuscular injection
Typical commercial role	Testosterone replacement and androgen therapy
Pharmacokinetic profile	Short acting
Regulatory classification in the U.S.	Controlled substance, Schedule III
Primary competitors	Testosterone cypionate, testosterone enanthate, testosterone undecanoate, gels, patches, pellets
Product type	Small-molecule pharmaceutical
Biosimilar exposure	None

The short half-life creates a need for more frequent administration than longer-acting injectable products. That reduces convenience for patients and clinicians, particularly in routine testosterone replacement therapy.

How large is the testosterone propionate market?

The standalone testosterone propionate market is a niche within the broader testosterone replacement market. Public market reports generally aggregate testosterone products by therapeutic class or dosage form and do not isolate propionate revenue with sufficient precision.

The broader testosterone market includes:

• Injectable testosterone cypionate and enanthate
• Long-acting testosterone undecanoate
• Transdermal gels and solutions
• Transdermal patches
• Buccal systems
• Subcutaneous pellets
• Oral testosterone undecanoate
• Compounded testosterone products

Testosterone propionate competes primarily on established clinical familiarity and low formulation complexity. It does not have the dosing convenience of testosterone undecanoate or the reimbursement and distribution scale of the dominant cypionate and enanthate products.

The commercial market is fragmented among branded products, generic injectables, contract manufacturers, specialty pharmacies, and compounding pharmacies. In the United States, testosterone propionate is more likely to generate small, distributed revenue streams than large branded-product revenue.

What is driving demand for testosterone propionate?

Demand is supported by several structural factors:

1. Continued diagnosis and treatment of male hypogonadism.
2. Use in specialized hormone-management practices.
3. Demand for injectable dosage forms.
4. Physician familiarity with esterified testosterone.
5. Compounding pharmacy demand where commercial product availability is limited.

Demand is constrained by the product’s short duration of action. Physicians often prefer testosterone cypionate or enanthate because those products support less frequent dosing. Testosterone undecanoate competes at the premium end of the market through longer dosing intervals, although it has higher administration and monitoring requirements.

FDA labeling for testosterone products requires treatment of confirmed hypogonadism associated with an underlying medical condition. The FDA has also required class-wide labeling changes concerning blood-pressure increases and cardiovascular risk information for testosterone products [1].

When does testosterone propionate lose exclusivity?

Testosterone propionate has no meaningful remaining composition-of-matter exclusivity in the United States. The molecule and ester have been used for decades, and any original patent protection has expired.

Exclusivity category	Current commercial relevance
Composition-of-matter patent	Expired
Basic ester chemistry	Expired
Original product patent	Expired or commercially irrelevant
Formulation patent	Limited and product-specific
Method-of-use patent	Limited; no clear product-wide barrier
Regulatory exclusivity	No meaningful current exclusivity expected
Orphan exclusivity	Not applicable
Pediatric exclusivity	Not applicable

The market is therefore exposed to generic entry and compounded alternatives. Any current commercial protection would arise from manufacturing know-how, supply agreements, regulatory approvals, distribution access, or customer relationships rather than from core patent rights.

What is the Orange Book status of testosterone propionate?

The Orange Book is relevant only to FDA-approved products and their listed patents. Testosterone propionate does not have a commercially significant active patent estate comparable to newer branded drugs.

The critical distinction is between:

• An FDA-approved testosterone propionate product with an active application.
• A discontinued or dormant product historically associated with testosterone propionate.
• A compounded preparation, which is not an FDA-approved finished drug.
• An imported or international product not approved for commercial distribution in the United States.

Orange Book-listed patents, where present for a specific product, would need to be assessed at the application level. They would not create broad exclusivity for testosterone propionate as a molecule. FDA’s Orange Book and Drugs@FDA databases remain the controlling sources for application status, therapeutic-equivalence information, and patent listings [2, 3].

What patents protect testosterone propionate?

No active patent category is likely to block ordinary manufacture of the testosterone propionate molecule. Potentially relevant rights are narrower:

Formulation patents

A manufacturer could seek protection for:

• A particular oil vehicle
• Preservative systems
• Solubility-enhancing excipients
• Low-volume injection formulations
• Packaging configurations
• Sterilization or stability systems

These rights would protect a specific formulation, not testosterone propionate generally. A competing manufacturer could often design around them using a different excipient system or concentration.

Manufacturing patents

Manufacturing-related rights could cover:

• Esterification processes
• Purification methods
• Crystallization
• Removal of residual solvents
• Sterile filling
• Stability-improvement processes

Such patents may create process advantages but are unlikely to prevent production using established alternative chemistry.

Method-of-use patents

Testosterone propionate could be covered by narrow method claims involving a particular patient population, dosing regimen, or administration protocol. Broad method-of-use exclusivity is unlikely because testosterone replacement has been practiced for many years and the active ingredient has extensive prior art.

How strong is the testosterone propionate patent estate?

The patent estate is weak from a blocking perspective and moderate only as a potential source of formulation or process differentiation.

Patent factor	Assessment
Core molecule protection	None of commercial significance
Ester protection	Expired
Broad formulation protection	Unlikely
Manufacturing barriers	Possible but design-around risk is high
Method-of-use protection	Narrow and vulnerable to prior art
Freedom-to-operate risk	Low for standard formulations
Generic entry risk	High
Litigation risk	Low relative to branded specialty drugs

The more important barriers are regulatory execution, sterile manufacturing validation, controlled-substance compliance, supplier qualification, and reliable distribution.

Which products compete with testosterone propionate?

Testosterone propionate competes against products with materially different commercial profiles.

Product	Dosing profile	Commercial position	Competitive effect
Testosterone cypionate	Longer acting	Widely used generic injectable	Strongest direct substitute
Testosterone enanthate	Longer acting	Established injectable	Strong substitute
Testosterone undecanoate	Long acting	Premium branded or specialty product	Competes on convenience
Topical testosterone gel	Daily	Broad outpatient use	Competes on noninvasive administration
Testosterone pellets	Long acting	Procedure-based specialty use	Competes on adherence
Oral testosterone undecanoate	Oral	Premium oral option	Competes on convenience
Compounded testosterone	Variable	Specialty and cash-pay channels	Competes on customization and availability

Testosterone cypionate is generally the most important direct commercial comparator because it is injectable, widely recognized, and more convenient for routine therapy.

What is the FDA regulatory status of testosterone propionate?

Testosterone products are regulated as prescription drugs and controlled substances. The FDA has increased scrutiny of testosterone replacement products, particularly around indication, cardiovascular risk, blood pressure, and appropriate patient selection [1].

A company commercializing testosterone propionate in the United States would need to address:

• FDA approval or an applicable lawful compounding pathway
• Current good manufacturing practice compliance
• Sterility assurance
• Container-closure integrity
• Controlled-substance controls
• Labeling and prescribing restrictions
• Pharmacovigilance
• Supply-chain security
• State pharmacy and wholesale-distribution requirements

Compounded testosterone propionate does not have the same premarket approval, manufacturing oversight, or therapeutic-equivalence designation as an FDA-approved finished product. That distinction affects payer coverage, physician confidence, substitution rules, and liability exposure.

Are there Paragraph IV challenges involving testosterone propionate?

Paragraph IV litigation is unlikely to be commercially material for testosterone propionate because the product has no prominent, high-value patent barrier. A generic applicant would normally challenge listed patents only where a relevant FDA-approved reference product has unexpired Orange Book patents.

The principal generic-entry pathway is therefore not a high-value patent challenge. It is approval, supply reliability, and market access. Potential disputes are more likely to involve:

• ANDA approval timing
• Product quality
• Manufacturing deficiencies
• Therapeutic equivalence
• Importation or distribution
• Controlled-substance compliance
• Compounding boundaries

Does testosterone propionate face biosimilar risk?

No. Testosterone propionate is a chemically synthesized small molecule, not a biologic. Biosimilar approval pathways do not apply.

Its competitive exposure is generic substitution, not biosimilar substitution. This generally produces more price pressure because manufacturers can compete through abbreviated regulatory pathways and standard pharmaceutical manufacturing.

What litigation affects testosterone propionate?

There is no widely recognized, high-value patent litigation campaign centered on testosterone propionate comparable to litigation involving major branded drugs. The litigation profile is more likely to involve product liability, controlled-substance enforcement, manufacturing compliance, or disputes over compounded products.

Broader testosterone litigation has included product-liability claims and regulatory disputes concerning cardiovascular safety and prescribing practices. Those matters affect the testosterone category but do not create proprietary protection for testosterone propionate.

What licensing deals involve testosterone propionate?

Large licensing transactions centered exclusively on testosterone propionate are unlikely. The product is too mature and commercially fragmented to support the deal structures common for novel drugs.

Potential transactions are more likely to involve:

• Contract manufacturing
• API supply
• Private-label injectable products
• Specialty-pharmacy distribution
• Compounding supply relationships
• Regional commercialization rights

Deal economics would depend on manufacturing cost, regulatory status, sterile-fill capacity, and distribution rights rather than on patent exclusivity.

What is the financial trajectory for testosterone propionate?

The expected trajectory is mature, low-growth, and price-sensitive.

Near-term outlook

Revenue should remain concentrated in niche clinical channels, specialty prescribers, international markets, and compounded products. Volume may be stable where prescribers specifically prefer short-acting testosterone, but substitution toward cypionate, enanthate, and newer delivery systems limits expansion.

Medium-term outlook

Pricing pressure is likely to persist because:

• Core patents are expired.
• Generic and compounded alternatives exist.
• Buyers can switch to other testosterone esters.
• Payers have limited incentive to reimburse a short-acting product at a premium.
• Sterile injectable manufacturing can produce supply interruptions and compliance costs.

Long-term outlook

The product is unlikely to regain broad commercial importance unless a manufacturer develops a differentiated delivery system, improves tolerability, secures a specialized indication, or exploits an underserved geographic market. A conventional testosterone propionate injection is more likely to remain a low-volume established product than become a major growth asset.

No major company publicly discloses testosterone propionate revenue separately. Financial exposure should therefore be modeled through product-level assumptions rather than reported segment revenue.

What generic launch scenarios exist?

Scenario	Market outcome	Financial effect
Single approved supplier	Higher supply sensitivity and pricing stability	Attractive niche margins
Multiple generic suppliers	Rapid price erosion	Lower margins, higher volume requirement
Commercial product shortage	Temporary demand shift to compounders or substitutes	Short-term revenue opportunity
Increased use of cypionate or enanthate	Structural substitution	Long-term volume decline
Regulatory action against compounding	Shift toward approved products	Potential volume benefit for compliant manufacturers
Sterile-manufacturing disruption	Product shortages and lost sales	Material downside for small suppliers

The strongest commercial opportunity is not patent-protected pricing. It is dependable supply in a market where sterile injectable shortages, supplier exits, or regulatory actions can create temporary openings.

What geographic markets are relevant?

The United States remains important because of its large testosterone-replacement market and established specialty-pharmacy infrastructure. Europe, Latin America, the Middle East, and parts of Asia have different prescribing patterns, reimbursement systems, controlled-substance rules, and product registrations.

Geographic expansion would require country-specific review of:

• Marketing authorization
• Prescription classification
• Testosterone import controls
• Anti-doping regulation
• Pharmacovigilance
• Local manufacturing or packaging
• Reimbursement
• Distribution licensing

An international product may not be legally interchangeable with a U.S. FDA-approved product, and U.S. compounding rules do not establish international market authorization.

Key Takeaways

• Testosterone propionate is a mature, short-acting injectable androgen with limited standalone commercial scale.
• Core patent protection has expired, and the molecule has no meaningful current exclusivity barrier.
• The main competitors are testosterone cypionate and testosterone enanthate, followed by testosterone undecanoate, gels, pellets, and oral products.
• Generic-entry risk is high, while Paragraph IV and biosimilar risks are low.
• Commercial value depends more on sterile manufacturing, supply continuity, regulatory status, and distribution than on patents.
• No major pharmaceutical company publicly reports testosterone propionate revenue separately.
• The financial outlook is stable to declining for conventional products, with temporary upside possible during supply disruptions or regulatory changes affecting compounded alternatives.

FAQs

Is testosterone propionate still commercially manufactured?

It may remain available through limited commercial, international, or compounded channels, but availability varies by jurisdiction and supplier. It does not have the broad commercial presence of testosterone cypionate or enanthate.

Is testosterone propionate cheaper than testosterone cypionate?

The active pharmaceutical ingredient may be inexpensive, but finished-product pricing depends on sterile filling, packaging, controlled-substance compliance, channel margins, and supply conditions. Testosterone cypionate generally has greater manufacturing scale and broader market availability.

Can a company obtain patent protection for a new testosterone propionate injection?

A company may pursue patents for a novel formulation, delivery system, manufacturing process, or dosing regimen. It cannot restore broad exclusivity over the established testosterone propionate molecule.

Is compounded testosterone propionate FDA approved?

A compounded preparation is not equivalent to an FDA-approved finished drug. Its legal status depends on the applicable compounding pathway, facility, prescription basis, and federal and state requirements.

What is the main investment risk in testosterone propionate?

The primary risk is commercial substitution. Physicians and patients can move to longer-acting testosterone esters, topical products, pellets, or oral formulations, limiting pricing power and long-term volume growth.

References

1. U.S. Food and Drug Administration. (2025). Testosterone information. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/testosterone-information

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2025). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Drug Enforcement Administration. (2024). Controlled substance schedules. https://www.deadiversion.usdoj.gov/schedules/

5. U.S. Food and Drug Administration. (2020). Testosterone products: Drug safety communication. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/testosterone-products-drug-safety-communication-fda-cautions-about-using-testosterone-products-low-testosterone-due-aging